Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials-Reference-Cited by-同舟云学术

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials

Published:2014-09-08 Issue:3 Volume:54 Page:471-481
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Robson J.,Doll H.,Suppiah R.,Flossmann O.,Harper L.,Hoglund P.,Jayne D.,Mahr A.,Westman K.,Luqmani R.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/54/3/471/6700363/keu366.pdf

Reference23 articles.

1. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis

2. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

3. Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)

4. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved Hearing Impairment of Granulomatosis with Polyangiitis Treated with Rituximab and Avacopan without Glucocorticoids;Internal Medicine;2024-09-01

2. Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World Setting;Kidney International Reports;2024-09

3. An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis;Clinical and Experimental Immunology;2024-08-14

4. Burden of eosinophilic granulomatosis with polyangiitis in Europe;ERJ Open Research;2024-05-02

5. Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use;BMC Rheumatology;2024-04-28